在接受长期间歇性置换治疗的危急病患者中服用 levetiracetam
Sirichai Chusiri1, Jirapat Vamananda2, Dhakrit Rungkitwattanakul3
1Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok 10330, Thailand.
Journal of critical care
|August 24, 2025
概括
对于长期间歇性置换疗法 (PIRRT) 接受的重症患者,标准的 levetiracetam 剂量可能不足. 最佳的剂量取决于PIRRT类型,频率和有效控制的时间.
科学领域:
- 药理动力学和药理动力学
- 危急护理医学
- 肝脏病学
背景情况:
- 利维通常用于预防和治疗发作.
- 长期间歇性置换疗法 (PIRRT) 可以显著影响药物清除.
- 对于接受PIRRT的重症患者,存在限定的服用指南.
研究的目的:
- 在接受PIRRT的重症成年人中评估 levetiracetam疗程实现目标 (PTA) 的概率.
- 确定最佳的 levetiracetam 剂量策略以达到治疗性药物暴露.
主要方法:
- 开发了一种具有第一阶排泄的单间药理动力学模型.
- 用蒙特卡洛模拟 (MCS) 来评估不同的 levetiracetam疗程.
- 模拟包括不同的PIRRT方式 (血液过,血液透析),排泄率,持续时间和药物给药时间.
主要成果:
- 在模拟的PIRRT场景中,常见的 levetiracetam剂量方案未能达到足够的PTA.
- 根据PIRRT方式和频率,最佳治疗方案有所不同.
- 对于交替日血过,500 mg每12小时或1000 mg每24小时是最优的;对于血液透析,750 mg每12小时或1250 mg每24小时是最优的.
- 每日PIRRT需要750毫克每12小时以始终达到PTA目标.
结论:
- 对于接受PIRRT治疗的患者来说,标准的 levetiracetam 剂量可能不足.
- 考虑到PIRRT的特点,需要个性化剂量策略.
- 需要对这些模拟剂量建议进行临床验证.
相关概念视频
Renal Failure: Dose Adjustments
153
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
153
Continuous Renal Replacement Therapy
141
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
141
Acute Kidney Injury V: Interprofessional Care
44
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
44
Acute Kidney Injury VI: Nursing Management
57
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
57
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446


